Main Article Content


Background The failure of the pancreatic islets to maintain normal blood glucose concentrations is not observed in clinical manifestations until irreversible damage has occurred. There is no effective biomarker yet to predict type 2 diabetes. MicroRNAs (miRNAs) are single non-coding RNA molecules. And miRNAs play a vital role in inhibiting the translation of post-transcriptional mRNAs. Studies in recent years have revealed that these microparticles play an essential role in the pathogenesis of type 2 diabetes. In addition, the presence of miRNAs in serum and plasma also provides a potential target for detecting disease markers. This study aims to investigate miR-204 in obese patients with type 2 diabetes.

Methods: Here we had collected 180 blood samples from 60 normal individuals, 60 patients with T2DM with a BMI of less than 30 and 60 patients with T2DM with a BMI of more than 30. The age of the subjects was 48-72 years . That's 85 males and 95 females. We used real-time Stem-loop PCR to detect miR-204 in the plasma of obese patients with type 2 diabetes.

Results: The results showed that plasma miR-204 levels were increased significantly in patients with T2DM in compared to normal individuals (P>0.001). Then we were also showed that serum miR-204 in Obese- T2DM groups were significantly higher than non-Obese- T2DM group. (2-sided Student’s t test P < 0.001). the results showed that there was no significant relationship between age and sex with miR-204 (P=0. 591 and 0.490 for age and sex, respectively). Our results showed that there was a statistical significant difference between BMI of all individuals with miR-204 expression. We showed that 56.1% of none obese individuals were low expression of miR-204 suggesting that increasing BMI leads to increasing level of miR-204 (P=0.001).

Conclusion: The Measuring circulating miR-204 is provide a relatively simple and straight forward approach, making it attractive for potential wider clinical application. However, identifying miR-204 could provide the necessary sensitivity and specificity to be detected in T2D.


miR-204 Obesity Plasma Type 2 diabetic

Article Details

How to Cite
Aldrisaoi, D. M. S., & Abdallah , A. A. (2023). Evaluation of miR-204 Serum Level in Obese Patients with Type 2 Diabetes. Central Asian Journal of Medical and Natural Science, 4(3), 247-256.


  1. 1. Ozougwu J, Obimba K, Belonwu C, Unakalamba CJJop, pathophysiology. The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. 2013;4(4):46-57.
  2. 2. Wu F, Yang L, Hang K, Laursen M, Wu L, Han GW, et al. Full-length human GLP-1 receptor structure without orthosteric ligands. 2020;11(1):1-10.
  3. 3. Kautzky-Willer A, Harreiter J, Pacini GJEr. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. 2016;37(3):278-316.
  4. 4. Dendup T, Feng X, Clingan S, Astell-Burt TJIjoer, health p. Environmental risk factors for developing type 2 diabetes mellitus: a systematic review. 2018;15(1):78.
  5. 5. Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med. 1998;15(7):539-53.
  6. 6. Blair MJUn. Diabetes Mellitus Review. 2016;36(1).
  7. 7. Definition W. Diagnosis and Classification of Diabetes Mellitus and its Complications Report of a WHO Consultation Part 1: Diagnosis and Classification of Diabetes Mellitus. 1999. World Health Organization, Geneva, Switzerland WHO/NCD/NCS/992 p. 2017;59.
  8. 8. Jehan S, Myers AK, Zizi F, Pandi-Perumal SR, Jean-Louis G, McFarlane SIJSm, et al. Obesity, obstructive sleep apnea and type 2 diabetes mellitus: Epidemiology and pathophysiologic insights. 2018;2(3):52.
  9. 9. Min M, Li-Fa X, Dong H, Jing W, Ming-Jie BJIjoph. Dietary patterns and overweight/obesity: a review article. 2017;46(7):869.
  10. 10. Romero-Cordoba SL, Salido-Guadarrama I, Rodriguez-Dorantes M, Hidalgo-Miranda A. miRNA biogenesis: biological impact inthe development of cancer. Cancer Biol Ther. 2014;15(11):1444-55.
  11. 11. Cui X, You L, Zhu L, Wang X, Zhou Y, Li Y, et al. Change in circulating microRNA profile of obese children indicates future risk of adult diabetes. 2018;78:95-105.
  12. 12. Wang R, Ding Y-D, Gao W, Pei Y-Q, Yang J-X, Zhao Y-X, et al. Serum microRNA-204 levels are associated with long-term cardiovascular disease risk based on the Framingham risk score in patients with type 2 diabetes: results from an observational study. Journal of Geriatric Cardiology: JGC. 2020;17(6):330.
  13. 13. Jo S, Chen J, Xu G, Grayson TB, Thielen LA, Shalev A. miR-204 controls glucagon-like peptide 1 receptor expression and agonist function. Diabetes. 2018;67(2):256-64.
  14. 14. Achkar NP, Cambiagno DA, Manavella PA. miRNA biogenesis: a dynamic pathway. Trends in Plant Science. 2016;21(12):1034-44.
  15. 15. Assou S, Al-Edani T, Haouzi D, Philippe N, Lecellier C-H, Piquemal D, et al. MicroRNAs: new candidates for the regulation of the human cumulus–oocyte complex. Hum Reprod. 2013;28(11):3038-49.
  16. 16. Kramer MF. Stem‐loop RT‐qPCR for miRNAs. Curr Protoc Mol Biol. 2011;95(1):15.0. 1-.0. .
  17. 17. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microRNAs by stem–loop RT–PCR. Nucleic Acids Res. 2005;33(20):e179-e.
  18. 18. Assmann TS, Recamonde-Mendoza M, Punales M, Tschiedel B, Canani LH, Crispim D. MicroRNA expression profile in plasma from type 1 diabetic patients: Case-control study and bioinformatic analysis. Diabetes Res Clin Pract. 2018;141:35-46.
  19. 19. Liu L, Yan J, Xu H, Zhu Y, Liang H, Pan W, et al. Two novel microRNA biomarkers related to β-cell damage and their potential values for early diagnosis of type 1 diabetes. The Journal of Clinical Endocrinology & Metabolism. 2018;103(4):1320-9.
  20. 20. Xu G, Chen J, Jing G, Grayson TB, Shalev A. miR-204 targets PERK and regulates UPR signaling and β-cell apoptosis. Mol Endocrinol. 2016;30(8):917-24.